International Clinical Trial: A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous dose escalation of GenSci098 in patients with diffuse toxic goiter

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121817) titled 'A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous dose escalation of GenSci098 in patients with diffuse toxic goiter' on April 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of China Medical University

Condition: Diffuse toxic goiter

Intervention: Cohort 1 (90 mg):GenSci098 90 mg, single subcutaneous injection Cohort 2 (180 mg):GenSci098 180 mg, single subcutaneous injection

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2026-04-07

Target Sa...